A cost-effectiveness approach to the qualification and acceptance of biomarkers

Stephen A. Williams, David E. Slavin,John A. Wagner, Christopher J. Webster

Nature Reviews Drug Discovery（2006）

引用 58|浏览5

暂无评分

摘要

Existing guidance for the validation of biomarkers is subjective and prone to bias resulting from stakeholder interests. Williams and colleagues describe an approach in which biomarkers could be qualified according to their 'cost-effectiveness' using a set of 'good practice' principles.

查看译文

关键词

Biomedicine,general,Pharmacology/Toxicology,Biotechnology,Medicinal Chemistry,Molecular Medicine,Cancer Research

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要